These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30647436)

  • 1. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
    Chashmniam S; Mirhafez SR; Dehabeh M; Hariri M; Azimi Nezhad M; Nobakht M Gh BF
    Eur J Clin Nutr; 2019 Sep; 73(9):1224-1235. PubMed ID: 30647436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of curcumin with piperine supplementation on pro-oxidant and antioxidant balance in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
    Mirhafez SR; Farimani AR; Gholami A; Hooshmand E; Tavallaie S; Nobakht M Gh BF
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Mirhafez SR; Farimani AR; Dehhabe M; Bidkhori M; Hariri M; Ghouchani BF; Abdollahi F
    J Gastrointestin Liver Dis; 2019 Jun; 28():183-189. PubMed ID: 31204416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
    Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S
    Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease.
    Saadati S; Hatami B; Yari Z; Shahrbaf MA; Eghtesad S; Mansour A; Poustchi H; Hedayati M; Aghajanpoor-Pasha M; Sadeghi A; Hekmatdoost A
    Eur J Clin Nutr; 2019 Mar; 73(3):441-449. PubMed ID: 30610213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Farsi F; Mohammadshahi M; Alavinejad P; Rezazadeh A; Zarei M; Engali KA
    J Am Coll Nutr; 2016; 35(4):346-53. PubMed ID: 26156412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial.
    Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A
    Drug Res (Stuttg); 2017 Apr; 67(4):244-251. PubMed ID: 28158893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial.
    Hariri M; Gholami A; Mirhafez SR; Bidkhori M; Sahebkar A
    Complement Ther Med; 2020 Jun; 51():102447. PubMed ID: 32507446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial.
    Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K
    Trials; 2018 Nov; 19(1):634. PubMed ID: 30445988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial.
    Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A
    J Cardiovasc Pharmacol; 2016 Sep; 68(3):223-9. PubMed ID: 27124606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.
    Rahmani S; Asgary S; Askari G; Keshvari M; Hatamipour M; Feizi A; Sahebkar A
    Phytother Res; 2016 Sep; 30(9):1540-8. PubMed ID: 27270872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
    Pervez MA; Khan DA; Ijaz A; Khan S
    Turk J Gastroenterol; 2018 Mar; 29(2):170-176. PubMed ID: 29749323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial.
    Saberi-Karimian M; Keshvari M; Ghayour-Mobarhan M; Salehizadeh L; Rahmani S; Behnam B; Jamialahmadi T; Asgary S; Sahebkar A
    Complement Ther Med; 2020 Mar; 49():102322. PubMed ID: 32147075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin supplementation improves biomarkers of oxidative stress and inflammation in conditions of obesity, type 2 diabetes and NAFLD: updating the status of clinical evidence.
    Mokgalaboni K; Ntamo Y; Ziqubu K; Nyambuya TM; Nkambule BB; Mazibuko-Mbeje SE; Gabuza KB; Chellan N; Tiano L; Dludla PV
    Food Funct; 2021 Dec; 12(24):12235-12249. PubMed ID: 34847213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol.
    Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
    BMJ Open; 2017 Jul; 7(7):e016914. PubMed ID: 28698350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial.
    Mirhafez SR; Dehabeh M; Hariri M; Farimani AR; Movahedi A; Naderan RD; Jamialahmadi T; Simental-Mendía LE; Sahebkar A
    Adv Exp Med Biol; 2021; 1328():11-19. PubMed ID: 34981468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
    Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Mirhafez SR; Azimi-Nezhad M; Dehabeh M; Hariri M; Naderan RD; Movahedi A; Abdalla M; Sathyapalan T; Sahebkar A
    Adv Exp Med Biol; 2021; 1308():25-35. PubMed ID: 33861434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial.
    Cicero AFG; Sahebkar A; Fogacci F; Bove M; Giovannini M; Borghi C
    Eur J Nutr; 2020 Mar; 59(2):477-483. PubMed ID: 30796508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
    Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
    Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.